WuXi Biologics (Cayman)'s total inventories for the quarter that ended in Dec. 2025 was MXN3,531 Mil. WuXi Biologics (Cayman)'s average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was MXN3,936 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. WuXi Biologics (Cayman)'s Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was MXN3.53.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
WuXi Biologics (Cayman)'s Days Inventory for the
six
months ended in Dec. 2025 was 46.28.
Inventory Turnover measures how fast the company turns over its inventory within a year.
WuXi Biologics (Cayman)'s Inventory Turnover for the quarter that ended in Dec. 2025 was 3.94.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
WuXi Biologics (Cayman)'s Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.13.
WuXi Biologics (Cayman) (MEX:2269N) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
WuXi Biologics (Cayman)'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
WuXi Biologics (Cayman)'s Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
WuXi Biologics (Cayman) Total Inventories Related Terms
WuXi Biologics (Cayman) Total Inventories Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of MXN3,531 Mil mean?
WuXi Biologics (Cayman) (MEX:2269N) has a Total Inventories of MXN3,531 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Total Inventories too high?
WuXi Biologics (Cayman)'s current Total Inventories is MXN3,531 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Total Inventories compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Total Inventories of MXN3,531 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Total Inventories is MXN3,531 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Total Inventories of MXN3,531 Mil. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current Total Inventories is MXN3,531 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Total Inventories is MXN3,531 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
Total Inventories: MXN3,531 Mil
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
